Radiation: 1,109 Real Stories

1,109 stories match radiation. 868 of them mention chemotherapy.

Cancer Stories

Charlotte, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II Invasive Ductal Carcinoma: Charlotte's Survivor Story

Patient Info: Charlotte, Female | Stage II

Biomarkers: BRCA inherited mutation negative

As of September 2025, Charlotte had undergone bilateral mastectomy, removal of 2 lymph nodes, delayed wound healing, and radiation for Stage II invasive ductal carcinoma, and was focused on recovery and life after treatment.

Susan G. Komen
OutcomeSurvivorship / Completed Treatment
Shiva, who was diagnosed with Colorectal CancerColorectal Cancer

Colorectal Cancer: Shiva's Survivor Story

Patient Info: Shiva Sharma, Male, 40s

As of September 2025, Shiva described being told he was cancer-free after surgery and continued follow-up with scans every 6 months and regular colonoscopy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic rectal cancer: total scapulectomy improves pain and function

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: CEA 418 ng/mL preoperatively; 10.3 ng/mL postoperatively; 7.2 ng/mL at 7 months; 11.1 ng/mL at about 5 months postoperatively; 6.4 ng/mL at 8 months

Metastatic Site: liver, right acromion/scapula, left adrenal gland

The patient had meaningful pain relief and functional recovery after total scapulectomy, but later developed liver and left adrenal progression and remained on palliative chemotherapy with a positive response.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Breast CancerBreast Cancer

Triple-negative breast cancer history with later chest wall sarcomatoid carcinoma treated by embolization, ablation, and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Initial breast cancer was triple-negative. Later chest-wall lesion was weak ER-positive, PR/HER2-negative

By February 2025, the treated chest wall lesion had decreased to about 13 x 7 mm after embolization, radiofrequency ablation, and albumin-bound paclitaxel plus cisplatin, with no peripheral or distant metastatic foci seen.

PubMed Central
OutcomeResponding Well
Iris, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Iris's Patient Story

Patient Info: Iris, Female | Stage IV

Metastatic Site: Spine; liver; bone

As of August 2025, Iris was living with Stage IV metastatic breast cancer involving the spine, liver, and bones and was receiving systemic maintenance therapy with monthly injections and close monitoring.

Susan G. Komen
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed Central
OutcomeCancer-Free / NED
Allison, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV ALK Lung Adenocarcinoma: Allison's Patient Story

Patient Info: Allison, Female, 40s | Stage IV

Biomarkers: ALK-positive fusion; later ALK resistance mutations reported

Metastatic Site: Bone (spine, femur, ribs, shoulder); brain

Allison was living with Stage IV ALK-positive lung cancer and had a strong response to targeted therapy: brain lesions cleared, most PET activity resolved, and the primary tumor shrank to about 1.5 cm. As of August 2025, she remained on second-line targeted therapy.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic lung adenocarcinoma with brain and iliac bone response to chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1-negative; no EGFR, ALK, ROS1, RET, KRAS, BRAF, MET, HER2, or NTRK alteration detected; TP53 mutation found.

Metastatic Site: left iliac bone, brain

Brain metastases achieved complete remission without cranial irradiation, and lung, bone, and brain lesions remained stable at last follow-up, with PFS of 35 months and OS exceeding 40 months.

PubMed Central
OutcomeResponding Well
Marissa, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Marissa's Survivor Story

Patient Info: Marissa Coreno, Female, Under 40

Biomarkers: Tumor biomarkers not reported; no apparent genetic predisposition for breast cancer

As of August 2025, Marissa was 31, had no sign of cancer, and remained on estrogen-blocking therapy planned for 10 years after chemotherapy, bilateral mastectomies, reconstruction, radiation, a CDK 4/6 inhibitor pill and a bisphosphonate.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic breast cancer to the mandible with later lung and liver spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER/PR negative, HER2 weak-to-moderate.

Metastatic Site: mandible/bone, lungs, liver

She died 6 months after diagnosis of mandibular metastasis from breast cancer, after further spread to the lungs and liver.

PubMed Central
OutcomeIn Memory
Linda, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Linda's Patient Story

Patient Info: Linda Norman, Female, 60s | Stage IV

Metastatic Site: Bone: humerus/shoulder region

As of August 2025, Linda was 1 year into treatment for bone-metastatic breast cancer with letrozole, Verzenio, and bone-strengthening infusions; scans showed the tumor had not grown and bone scarring suggested healing.

Susan G. Komen
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

ROS1-rearranged Stage IV lung adenocarcinoma: sequential targeted therapy and 73-month survival

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: CD74-ROS1 C6:R33 fusion; CTNNB1 p.Thr41Ala; APC p.Glu601fs; acquired ROS1 resistance mutation; mTOR p. mutation; FGFR3 gene amplification

Metastatic Site: contralateral lung nodules, brain, pleura

She died on October 6, 2024, after sequential crizotinib, lorlatinib, and cabozantinib for Stage IV ROS1-rearranged lung adenocarcinoma, with total overall survival of 73 months from diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-Mutant Stage IV Lung Cancer Treated After Osimertinib-Related Lung Toxicity

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; later EGFR T790M resistance mutation

Metastatic Site: brain, lungs, bones, left adrenal gland, meninges

The latest documented treatment was a lower-dose osimertinib rechallenge with corticosteroids, which reduced the tumor without recurrence of the prior interstitial lung disease.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage IVA lung cancer with small-cell and adenocarcinoma components: mixed response before infection halted treatment

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 <1%

Metastatic Site: bone (C2, T10, sacral vertebrae); malignant pleural…

The lung cancer showed mixed responses, with right-lung small-cell progression after chemotherapy/immunotherapy and later treatment interruption because of severe lung infection and respiratory failure.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Man in his 80s with Stage IA1 lung cancer treated with adapted SBRT

Patient Info: Anonymized, Male

Biomarkers: CEA and CA19-9 not elevated; molecular biomarkers not reported

At 1 year after SBRT, CT showed radiation fibrosis and complete metabolic response, with no enlarging mass suggesting local recurrence; ongoing follow-up continued.

PubMed Central
OutcomeCancer-Free / NED
Clara, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Clara's Patient Story

Patient Info: Clara, Female, Under 40 | Stage IV

Biomarkers: Biomarker found but specific mutation not stated

Metastatic Site: Bone and joints; brain; liver/other organs

Clara was living with Stage IV metastatic lung cancer involving bone/joints, brain, and other organs. As of August 2025, she had received brain radiation and first-line chemotherapy plus immunotherapy, with ongoing lifelong immunotherapy planned.

The Patient Story
OutcomeLiving With Cancer
Kathy, who was diagnosed with Colorectal CancerColorectal Cancer

Colorectal Cancer: Kathy's Survivor Story

Patient Info: Kathy Ball-Toncic, Female, 60s

As of August 2025, Kathy had been declared cancer-free again in August 2024 after treatment for breast DCIS and a later colorectal cancer, rebuilt strength with physical therapy, and completed a 162-mile Pan-Mass Challenge ride.

Dana-Farber
OutcomeCancer-Free / NED
Jenny, who was diagnosed with Lung CancerLung Cancer

Lung Cancer: Jenny's Patient Story

Patient Info: Jenny, Female

Jenny died from lung cancer in November 2023. As of August 2025, her husband Kyle was raising their children, continuing her advocacy around lung cancer awareness, and preserving her legacy.

The Patient Story
OutcomeIn Memory
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Synchronous triple-negative breast cancer and rectal adenocarcinoma complicated by hepatitis B reactivation

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer with pathogenic BRCA1 mutation; hepatitis B reactivation occurred during treatment.

At 3-year follow-up, she remained healthy and disease-free after treatment for synchronous triple-negative breast cancer and mid-rectal adenocarcinoma, with hepatitis B reactivation controlled on entecavir.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast AdenocarcinomaBreast Cancer

Metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: HER2-positive breast cancer. Jaw workup focused on osteonecrosis

Metastatic Site: bone / osseous metastasis

The case focused on metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw after antiresorptive therapy; dental pain improved transiently after oral-surgery interventions, but systemic cancer response was not described.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic hormone receptor-positive breast cancer: palbociclib and fulvestrant during dialysis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2 0 / HER2-negative; Ki-67 20.1%

Metastatic Site: lung, pleura, bone, right supraclavicular lymph node

As of August 2025, metastatic breast cancer had remained stable for 18 months on fulvestrant plus dialysis-adjusted palbociclib dosing, with hematologic toxicity managed through treatment interruptions, transfusion, and dose reduction.

PubMed Central
OutcomeLiving With Cancer